ProCE Banner Activity

Phase I/II Trial of Flotetuzumab as Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Slideset Download
Conference Coverage
In a phase I/II trial, flotetuzumab showed encouraging activity and a manageable safety profile in patients with AML and primary induction failure or early relapse.

Released: December 15, 2020

Expiration: December 14, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology